Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OSI Pharmaceuticals
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• 18 years of age or older

• Advanced and/or metastatic solid tumor for which no effective therapy is available

• ECOG performance status 0-2

• Adequate bone marrow, hepatic and renal function

Exclusion Criteria:

• Patients with active or uncontrolled infections

• Neurotoxicity >= Grade 2

• Symptomatic brain metastases which are not stable